This article was originally published in The Rose Sheet
Executive SummaryOrtho Neutrogena's Retin-A Micro (tretinoin gel) .04% microspheres approved by FDA May 10. The .04% dosage joins four year-old .1% formulation of the topical gel for acne vulgaris. Labeling for new version states, "There is no evidence that Retin-A Micro .1% is more efficacious than Retin-A Micro .04% or that Retin-A Micro .04% is safer than Retin-A Micro .1%." Ortho Neutrogena was formed in July 2001 when Ortho Dermatological and the professional division of Neutrogena were combined...
You may also be interested in...
Lucky STAR: FDA’s eSTAR Pilot Aims To Make 510(k) Process Smoother With Submission Template For Device Makers
Nine manufacturers will soon have the chance to enroll in a voluntary eSTAR pilot program that the US agency says will make the premarket review process more efficient and consistent. The design and structure of an electronic Submission Template And Resource – or eSTAR – template is similar to templates used by FDA reviewers. An eSTAR won’t change the agency’s statutory or data requirements for sponsors to show substantial equivalence to predicate devices.
W3ll People is expected to add a relatively modest $7m to e.l.f. Beauty’s fiscal 2021 top line, but the brand has “major white space” opportunities, including at Target, e.l.f.’s longest-standing customer. Further, its plant-based product line includes 40 “EWG Verified” products, reflecting expertise e.l.f. is eager to tap.
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.